The BCCA is an agency of the Canadian Provincial Health Services Authority.

The British Columbia Cancer Agency’s (BCCA) Genome Science Center has joined the Illumina Genome Network (IGN). IGN is designed to link researchers needing large-scale whole human genome sequencing with leading institutions that provide this application as a service using Illumina platforms.

“The BCCA Genome Science Center has earned a reputation as a key source of innovative genomic research and analysis, and we are pleased their wealth of experience will now be available through the Illumina Genome Network,” said Tristan Orpin, svp and chief commercial officer at Illumina.

“Illumina sequencers have powered our research into the human genome and enabled us to make significant contributions to Canadian and international sequencing projects,” remarks Marco Marra, Ph.D., director of the BCCA Genome Science Center. “We are looking forward to working with other researchers in their efforts to illuminate the changes in the human genome that impact biological mechanisms.”

The BCCA is an agency of the Canadian Provincial Health Services Authority. It works with community partners to deliver a range of oncology services including prevention, early detection, diagnosis and treatment, research, education, supportive care, rehabilitation, and palliative care.

The BCCA joins the University of Washington Department of Genome Sciences, National Center for Genome Resources, Macrogen/Genomic Medicine Institute, and Illumina’s own FastTrack Services lab as members of the Illumina Genome Network.

All IGN partners are experienced and well-published using Illumina TruSeq™ technology and have completed Illumina’s certified service provider (CSPro®) certification. Each possesses 10 or more Illumina sequencing systems (HiSeq 2000 systems and/or Genome Analyzers), providing the scalability to handle even the largest sequencing projects with rapid completion times.

Previous articlePall to Take Over ForteBio for Protein Analysis Systems
Next articleAgenus, NewVac Ink Cancer Vaccine Deal in Russia